A5079022151- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Genetic factors in colorectal cancer
- Microtubule and mitosis dynamics
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- Virus-based gene therapy research
- Ferroptosis and cancer prognosis
- Gastric Cancer Management and Outcomes
- Histone Deacetylase Inhibitors Research
- Chemokine receptors and signaling
- Breast Cancer Treatment Studies
- Esophageal Cancer Research and Treatment
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Colorectal Cancer Treatments and Studies
- Cancer, Hypoxia, and Metabolism
- Inflammatory mediators and NSAID effects
Roswell Park Comprehensive Cancer Center
2016-2025
Washington University in St. Louis
2019-2025
Indiana University Health
2022-2025
Indiana University – Purdue University Indianapolis
2022-2025
Indiana University Indianapolis
2024
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
2022-2024
Indiana University
2023-2024
Indiana University School of Medicine
2022-2024
University of Indianapolis
2024
Indiana University Bloomington
2022
Signals mediated by the chemokine CXCL12 and its receptor CXCR4 are involved in progression of ovarian cancer through enhancement tumor angiogenesis immunosuppressive networks that regulate dissemination peritoneal metastasis development cancer-initiating cells (CICs). In this study, we investigated antitumor efficacy a antagonist expressed oncolytic vaccinia virus (OVV) against an invasive variant murine epithelial cell line ID8-T. This harbors high frequency CICs form multilayered spheroid...
New therapies are needed to treat immune checkpoint inhibitor-resistant non-small cell lung cancer (NSCLC) and identify biomarkers personalize treatment. Epigenetic therapies, including histone deacetylase inhibitors, may synergize with programmed death-1 (PD-1) blockade overcome resistance. We report outcomes in patients anti-programmed death ligand-1 [PD-(L)1]-resistant/refractory NSCLC treated pembrolizumab plus entinostat ENCORE 601.The expansion cohort of 601 included who previously...
The aim of the study was to investigate if there were differences in associations stromal versus intratumoral tumor infiltrating lymphocytes (TILs) with pathology complete response (pCR) among breast cancer (BC) subtypes treated neoadjuvant therapy.The hematoxylin and eosin slides BC-core biopsy consecutive cases (n=331) reviewed from a single institution between 2000 2014. TIL-stroma (TIL-str) scored 0% 100%. Intratumoral (iTu-Ly) semiquantitatively incorporating infiltrate grade (0 3)...
While immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape in oncology, they are effective select subsets of patients. Efficacy may be limited by tumor-driven suppression, which 1 key mechanism is development myeloid-derived suppressor cells (MDSCs). A fundamental gap MDSC therapeutics lack approaches that target biogenesis. We hypothesized targeting biogenesis would mitigate burden and bolster tumor responses to ICIs. tested a class agents, dihydroorotate...
Colorectal cancer (CRC) is a complex disease with diverse etiologies and clinical outcomes. Despite considerable progress in development of CRC therapeutics, challenges remain regarding the diagnosis management advanced stage metastatic (mCRC). In particular, five-year survival rate very low since mCRC currently rarely curable. Over past decade, treatment has significantly improved introduction immunotherapies, specifically immune checkpoint inhibitors. Therapies aimed at blocking...
Mechanically gated PIEZO channels lead to an influx of cations, activation additional Ca
The positive-sense transcripts of Sindbis virus (SINV) resemble cellular mRNAs in that they possess a 5' cap and 3' poly(A) tail. It is likely, therefore, SINV RNAs must successfully overcome the cytoplasmic mRNA decay machinery cell order to establish an efficient, productive infection. In this study, we have taken advantage temperature-sensitive polymerase shut off viral transcription, demonstrate are subject during infection both C6/36 (Aedes albopictus) baby hamster kidney cells....
Engineered measles virus (MV) strains deriving from the vaccine lineage represent a promising oncolytic platform and are currently being tested in phase I trials. In this study, we have demonstrated that MV genetically engineered to express human sodium iodide symporter (NIS) significant antitumor activity against glioma lines orthotopic xenografts; compares favorably with strain expressing carcinoembryonic antigen, which is clinical testing. Expression of NIS protein infected cells results...
Inflammatory breast cancer (IBC) is an angioinvasive and most aggressive type of advanced characterized by rapid proliferation, chemoresistance, early metastatic development poor prognosis. IBC tumors display a triple-negative (TNBC) phenotype centrosome amplification, high grade chromosomal instability (CIN) low levels expression estrogen receptor α (ERα), progesterone (PR) HER-2 tyrosine kinase receptor. Since the TNBC cells lack these receptors necessary to promote tumor growth, common...
DNA abnormalities are used in inclusion criteria of clinical trials for treatments with specific targeted molecules. MYC is one the most powerful oncogenes and known to be associated triple-negative breast cancer (TNBC). Its amplification often part DNA-sequencing panels under assumption reflecting upregulated signaling. However, it remains unclear if a surrogate its Thus, we investigated difference between mRNA high expression TNBCs utilizing publicly available cohorts. amplified tumors...
Breast cancer (BC) patients experience increased stress with elevated cortisol levels, increasing risk of recurrence. Cortisol binds to a cytoplasmic receptor, glucocorticoid receptor (GR) encoded by GR gene (NR3C1). We hypothesized that not only cells, but even immune cells in the tumor microenvironment (TME) may contribute expression bulk and influence prognosis. To test this, mRNA data was accessed from METABRIC TCGA. “High” “low” based on highest lowest quartiles NR3C1 expression,...
Abstract Background: Inhibitors of programmed death 1 (PD-1) and its ligand (PD-L1) have improved outcomes in patients (pts) with advanced melanoma, but treatment options for pts who progress on or after these therapies remain limited. In this group, we previously reported preliminary data that ENT, a class I selective histone deacetylase (HDAC) inhibitor, combination PEMBRO showed promising activity, through alteration the immunosuppressive tumor microenvironment. Here report full cohort...
Despite the approval of mTOR inhibitor everolimus and CDK4/6 inhibitors in management hormone-receptor-positive HER2 non-amplified metastatic breast cancer (HR+ HER2-MBC), optimal sequence therapy is unclear. There are no clinical data on efficacy HR+ HER2-MBC after progresses inhibitors.The objective this study to find they progress a palbociclib.This retrospective, 2-institute review from Jan 2015 March 2018 treated with progression palbociclib. Primary end point was median...
Background: Bimiralisib is a pan-PI3K/mTOR inhibitor demonstrating antitumor efficacy in preclinical models. The objectives of this study were to identify maximum tolerated dose (MTD), pharmacokinetics (PK), dosing schedule, and adverse events (AEs) patients with advanced solid tumors. Patients Methods: received oral bimiralisib determine the MTD one continuous (once daily) two intermittent schedules (A: Days 1, 2 weekly; B: 4 weekly) until progression or unacceptable AEs occurred. Results:...